


# CLEANING VALIDATION

## PRACTICAL COMPLIANCE SOLUTIONS FOR PHARMACEUTICAL MANUFACTURING

VOLUME 4



Destin A. LeBlanc

[www.pda.org/bookstore](http://www.pda.org/bookstore)

# **CLEANING VALIDATION**

**PRACTICAL  
COMPLIANCE  
SOLUTIONS FOR  
PHARMACEUTICAL  
MANUFACTURING**

Volume Four

Destin A. LeBlanc

PDA  
Bethesda, MD, USA  
DHI Publishing, LLC  
River Grove, IL, USA

10 9 8 7 6 5 4 3 2 1

**ISBN: 978-1-942911-04-3**

**Copyright © 2017 Destin A. LeBlanc**

**All rights reserved.**

All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system or transmitted in any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America.

Where a product trademark, registration mark, or other protected mark is made in the text, ownership of the mark remains with the lawful owner of the mark. No claim, intentional or otherwise, is made by reference to any such marks in the book. Websites cited are current at the time of publication. The author has made every effort to provide accurate citations. If there are any omissions, please contact the publisher.

While every effort has been made by the publisher and the authors to ensure the accuracy of the information expressed in this book, the organization accepts no responsibility for errors or omissions. The views expressed in this book are those of the editors and authors and may not represent those of either Davis Healthcare International or the PDA, its officers, or directors.



*Connecting People, Science and Regulation®*



This book is printed on sustainable resource paper approved by the Forest Stewardship Council. The printer, Gasch Printing, is a member of the Green Press Initiative and all paper used is from SFI (Sustainable Forest Initiative) certified mills.

**PDA Global Headquarters**

Bethesda Towers, Suite 600  
4350 East-West Highway  
Bethesda, MD 20814  
United States  
[www.pda.org/bookstore](http://www.pda.org/bookstore)  
001-301-986-0293

**Davis Healthcare International Publishing, LLC**

2636 West Street  
River Grove  
IL 60171  
United States  
[www.DHIBooks.com](http://www.DHIBooks.com)

[www.pda.org/bookstore](http://www.pda.org/bookstore)

# CONTENTS

<b>Foreword</b>	<b>vii</b>
<b>Health-Based Limits</b>	<b>I</b>
1. <i>What's a Potent Active?</i>	<b>3</b>
2. <i>Does Risk-MaPP Offer More Patient Protection?</i>	<b>7</b>
3. <i>Are Health-Based Limits Enough?</i>	<b>13</b>
4. <i>A Way Forward for "Health-Based" Limits</i>	<b>19</b>
5. <i>Shortcomings of ADE/PDE Values for Cleaning Validation</i>	<b>23</b>
6. <i>Route Specific Health-Based Limit Values</i>	<b>29</b>
7. <i>Duration Specific Health-Based Limit Values</i>	<b>33</b>
8. <i>Should 10-PPM be Used for Limits?</i>	<b>37</b>
9. <i>Comments on the EMA Draft Guideline         on Dedicated Facilities</i>	<b>43</b>
10. <i>EMA on Limits for Shared Facilities: Part 1</i>	<b>49</b>
11. <i>EMA on Limits for Shared Facilities: Part 2</i>	<b>55</b>
12. <i>EMA on Limits for Shared Facilities: Part 3</i>	<b>61</b>
13. <i>Meeting EMA Requirements for Existing Products</i>	<b>65</b>
<b>Limits for API Manufacture</b>	<b>69</b>
14. <i>Limits for Small Molecule API Synthesis: Part 1</i>	<b>71</b>
15. <i>Limits for Small Molecule API Synthesis: Part 2</i>	<b>77</b>
16. <i>Limits for Small Molecule API Synthesis: Part 3</i>	<b>83</b>

<b>Limits: General</b>	<b>87</b>
17. <i>Using Safety Factors of Less than 0.001 of a Dose</i>	89
18. <i>The 500 ppb TOC Myth</i>	93
19. <i>More on Limits Based on Compendial Water Values</i>	97
20. <i>Dealing with Preferential Transfer of Residues</i>	101
21. <i>Setting Limits for Cleaning Agents</i>	105
22. <i>Significance of GRAS</i>	111
23. <i>Limits for Products with Multiple Actives</i>	115
24. <i>Limits for Batch Splitting: Part 1</i>	119
25. <i>Limits for Batch Splitting: Part 2</i>	123
<b>Visually Clean</b>	<b>127</b>
26. <i>Regulatory Status of “Visually Clean Alone”</i>	129
27. <i>Special Cases in Determining “Visually Clean”</i>	133
<b>Sampling and Sampling Recovery</b>	<b>137</b>
28. <i>Comparing Swab and Rinse Results</i>	139
29. <i>Revisiting Linearity of Recovery Studies</i>	143
30. <i>Revisiting Rinse Sampling Recovery Studies</i>	147
31. <i>Recovery Studies for Different Surfaces         for Rinse Sampling</i>	151
32. <i>Sampling Recovery for Volatile Materials</i>	155
<b>Analytical Methods</b>	<b>159</b>
33. <i>Conductivity vs. pH vs. TOC for Final Rinse         Monitoring: Part 1</i>	161
34. <i>Conductivity vs. pH vs. TOC for Final Rinse         Monitoring: Part 2</i>	165
<b>Limits for Lyophilizers</b>	<b>169</b>
35. <i>Cleaning Validation Limits for Lyophilizers: Part 1</i>	171
36. <i>Cleaning Validation Limits for Lyophilizers: Part 2</i>	175
37. <i>Cleaning Validation Limits for Lyophilizers: Part 3</i>	179

<b>Protocols and Procedures</b>	<b>183</b>
38. <i>Is Pre-Cleaning Allowed?</i>	185
39. <i>Test Until Clean?</i>	189
40. <i>Mock Soils and Mock Soiling</i>	193
41. <i>Understanding Sources of Variation in Cleaning Processes</i>	197
42. <i>Understanding Sources of Variation in Validation Protocols</i>	201
43. <i>Only Read This if Applicable</i>	205
<b>Miscellaneous Topics</b>	<b>207</b>
44. <i>White Rings in Buffer Tanks</i>	209
45. <i>Issues in Equipment Grouping</i>	213
46. <i>Cleaning Validation for Continuous Manufacture</i>	217
47. <i>What's in Annex 15?</i>	221
48. <i>What is Placebo Sampling?</i>	227
49. <i>What is Placebo Cleaning?</i>	231
<b>Appendix A: Acronyms Used in this Volume</b>	<b>235</b>
<b>Appendix B: Shorthand Notations for Expressing Limits</b>	<b>237</b>
<b>Index</b>	<b>241</b>

---

---

## FOREWORD

This Volume 4 complements my earlier three books on the same subject. What are presented in this book are modifications and updates of my monthly *Cleaning Memos* originally published on my web site, [www.cleaningvalidation.com](http://www.cleaningvalidation.com), in the period from January 2013 through December 2016. Each *Cleaning Memo* is presented as a chapter, with the chapters then organized by common topics. For example, topics related to setting limits are in one section, those related to sampling in another section, and so forth. The updates made are sometimes relatively simple, and sometimes more detailed.

In all cases, I have tried to focus on changes for improving clarity and applicability, as well as to modify the text with new information. There is one appendix with a list of acronyms used in this volume, as well as a second appendix dealing with my shorthand method of expressing limits, just in case you get confused about what I mean by L0, L1, L2, L3 and L4.

A “hot topic” for these four years has been limits, and specifically health-based limits. More than half of these chapters deal with setting limits in one way or another, so the use of health-based limits will require balanced reading (and thinking) for an overall understanding.

I would also like to encourage pharmaceutical manufacturers, and particularly upper management, to meet the challenges of the science-based and risk-based approaches to cleaning validation. Using some of the principles and practices in this volume may help in designing a more effective and efficient cleaning validation program.

I should add a caveat here, much like the caveat before each of the FDA's guidance documents – nothing in this book should be considered mandatory or binding. I have tried to present alternatives where possible. However, achieving the same objectives by utilizing scientifically justified procedures that are applicable to a manufacturer's specific situation is strongly encouraged. In a manufacturing environment where process efficiencies as well as good compliance are mandatory, following "cookie cutter" recipes should be avoided.

**Coram Deo**

*Destin A. LeBlanc*

*Winter Haven, FL*

*February 2017*